Results 31 to 40 of about 22,433 (204)

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Diagnostic validity of Addictions Neuroclinical Assessment indices for alcohol use disorder: Findings from an observational case–control study

Addiction, EarlyView.
Abstract Background and aims The Addictions Neuroclinical Assessment (ANA) provides a framework for assessing alcohol use disorder (AUD) with indices that may be both mechanistically and diagnostically informative. This study evaluated an array of measures from the three ANA domains in relation to AUD diagnostic status. Design This cross‐sectional case–
Molly L. Garber, Carly McIntyre‐Wood, Mahmoud Elsayed, Michael T. Amlung, Lawrence H. Sweet, James MacKillop   +5 more
wiley   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

A Narrative Review on Bio-Physiology of Naltrexone Treatment in Pornography Addiction

Problematic pornography use remains a debatable entity, with features overlapping behavioral addictions and impulse control disorders. The controversial nosological status also provides challenges in formulating management plans as there exists no proven
Manoj Kumar Sharma, H. Ravish, Sidharth Arya   +2 more
core   +1 more source

Evaluation of a prison-based naltrexone program

, 2007
The study evaluated the introduction of naltrexone in an Australian prison system for imprisoned male heroin users. Treatment outcomes were analysed for two sub‐samples taken from an unsuccessful randomised controlled trial. The first sample comprised 68
Dolan, Kate A., Shearer, James; id_orcid, Wodak, Alex D.   +2 more
core   +1 more source

The association between sleep disturbance and stimulant use: A cross‐lagged examination

Addiction, EarlyView.
Abstract Background and aims Sleep disruptions increase the risk of substance misuse. Substance use—especially stimulants—can increase acute and chronic sleep dysfunction. This study aimed to estimate the associations between sleep disturbance and stimulant use over time among participants with stimulant use disorder (StUD).
Viviana E. Horigian, Renae D. Schmidt, Daniel J. Feaster, Rui Duan, Sophia T. Gonzalez, Kathryn Hefner, Dikla Shmueli‐Blumberg, Ashley Vena, Landhing M. Moran, Chloe A. DiCamillo, Shirin Shafazand, Susan Tross, Judith Feinberg   +12 more
wiley   +1 more source

Free naltrexone levels in dams and offspring with naltrexone implant.

, 2013
Temporal profiles of free naltrexone concentration are shown in offspring blood or amniotic fluid (A, cohort 1) or maternal blood (A and B, cohorts 1, 2 & 3.) after maternal administration with a naltrexone implant (25 mg, s.c.).
Robert J. Tait (292446), Sarah A. Dunlop (292448), Waleed O. Farid (292442), Gary K. Hulse (292447), Elena V. Krstew (292445), Andrew J. Lawrence (292444)   +5 more
core   +1 more source

Efficacy and safety of transcranial direct current stimulation in alcohol use disorder: A randomized controlled triple‐blind trial

Addiction, EarlyView.
Abstract Background and aims Current treatment options for alcohol use disorder are limited. Transcranial direct current stimulation has been proposed as a therapeutic approach, but evidence remains scarce. This study aimed to compare active vs. sham transcranial direct current stimulation to evaluate its efficacy and safety in reducing alcohol ...
Benoit Trojak, Anne Sauvaget, Wissam El Hage, Thomas Wallenhorst, Benjamin Rolland, Philippe Nubukpo, Ghina Harika‐Germaneau, David Szekely, Julie Giustiniani, Marc Auriacombe, Georges Brousse, Sébastien Guillaume, Maxime Bubrovszky, Benjamin Petit, Clémence Cabelguen, Hussein El Ayoubi, Suzanne Rankin, Agnès Soudry‐Faure, Karine Goueslard, Anastasia Demina   +19 more
wiley   +1 more source

Predictive validity of Alcohol Use Disorder Identification Test – Consumption (AUDIT‐C) for register‐based alcohol‐attributable events among general‐population men and women of different ages

Addiction, EarlyView.
Abstract Background and aims Originally developed for clinical screening for hazardous alcohol use, the Alcohol Use Disorder Identification Test – Consumption (AUDIT‐C) is also widely used in epidemiological research and monitoring. However, its cutoff values may not suit all purposes, and evidence on its predictive validity is limited. We examined how
Pia Mäkelä, Jaakko Reinikainen, Sarah Callinan, Marke Jääskeläinen, Kaisa Kuurne, Tomi Lintonen, Solja Niemelä, Jonna Levola   +7 more
wiley   +1 more source